Francine Kaufman
CIK 1769791 · View on SEC EDGAR ↗
First SEC filing: June 17, 2026 · Latest: June 17, 2026
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 11, 2022 | SENS | S | 163,870 | $2.46 | $403,120 | 1,222,175 Direct | -11.82% | Disposed | -81.1% (price as of 2026-08-21) |
| Nov. 16, 2021 | SENS | S 10b5-1 | 20,998 | $3.70 | $77,693 | 1,075,161 Direct | -1.92% | Disposed | -87.4% (price as of 2026-08-21) |
| June 11, 2021 | SENS | S 10b5-1 | 62,628 | $4.00 | $250,512 | 1,057,876 Direct | -5.59% | Disposed | -88.4% (price as of 2026-08-21) |
| June 4, 2021 | SENS | S 10b5-1 | 62,627 | $3.00 | $187,881 | 1,099,588 Direct | -5.39% | Disposed | -84.5% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 11, 2021 | SENS | Stock Option (right to buy) | Common Stock (20,916) | $3.07 | March 3, 2029 | 20,916 | Acquired |
| March 4, 2019 | SENS | Stock Option (right to buy) | Common Stock (550,000) | — | March 3, 2029 | 550,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
SENS
M.D. Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2020 | $510,000 | $117,045 | $578,343 | — | $112,445 | — | $8,550 | $1,326,383 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.